Conditions

GLP-1 for Prediabetes: Can It Reverse Insulin Resistance?

GLP-1 Companion · 8 min read

Prediabetes is not a minor variation in blood sugar levels — it is a critical warning window. Approximately 96 million American adults, or about 38% of the adult population, have prediabetes. Without intervention, an estimated 70% will develop type 2 diabetes within 10 years, setting the stage for cardiovascular disease, kidney disease, neuropathy, and significantly shortened lifespan. GLP-1 medications have produced the most powerful prediabetes reversal rates ever documented in a pharmacological intervention.

What Is Prediabetes?

Prediabetes is defined by blood glucose levels above normal but below the threshold for type 2 diabetes diagnosis. It is identified by any of the following criteria: fasting glucose between 100–125 mg/dL (impaired fasting glucose), HbA1c between 5.7% and 6.4%, or a 2-hour glucose of 140–199 mg/dL on an oral glucose tolerance test. The underlying problem is progressive insulin resistance — cells becoming increasingly unresponsive to insulin — combined with beta cell overwork that gradually exhausts the pancreas's ability to compensate.

STEP 1 Trial: 80% Return to Normal Blood Sugar

The most compelling data on GLP-1 therapy for prediabetes comes from the STEP 1 trial, which evaluated semaglutide 2.4mg weekly in adults with obesity. Among participants who had prediabetes at baseline, 80% returned to normoglycemia (HbA1c below 5.7%) after 68 weeks of treatment — compared to 48% in the placebo group. This extraordinary reversal rate far exceeds what any previous pharmacological intervention had achieved.

• 80% of prediabetic semaglutide participants achieved normoglycemia at 68 weeks, versus 48% with placebo.
• HbA1c decreased by an average of 0.4–0.5% across the full STEP 1 cohort, with larger decreases in those with higher baseline glucose levels.
• Fasting glucose normalized in the large majority of participants who achieved 15% or more body weight loss.
• Participants with the highest baseline HbA1c values (5.9–6.4%) showed proportionally larger glucose improvements than those with mildly elevated values.

CagriSema REDEFINE Trials: 88% Normalization Rate

CagriSema is an investigational fixed combination of semaglutide and cagrilintide (a long-acting amylin analogue) that represents the next generation of GLP-1-based therapy. In the REDEFINE 1 trial, 88% of participants with prediabetes at baseline returned to normal blood glucose — the highest rate of glycemic normalization ever reported for any pharmacological intervention in prediabetes.

While cagrilintide/semaglutide remains investigational as a fixed combination, the 88% figure underscores the trajectory of GLP-1-based therapy and the depth to which this drug class can restore normal glucose metabolism.

Mechanism: How GLP-1 Medications Reverse Insulin Resistance

The ability of GLP-1 medications to reverse prediabetes goes beyond simple weight loss. Multiple mechanisms work simultaneously:

• Pancreatic fat reduction. Visceral and ectopic fat deposited within and around the pancreas directly impairs beta cell insulin secretion. As GLP-1 therapy reduces this fat, beta cell function can partially or fully recover.
• Hepatic fat reduction. Liver fat (hepatic steatosis) drives insulin resistance in the liver — the largest contributor to fasting hyperglycemia. Reducing liver fat directly lowers fasting glucose.
• Direct incretin effects. GLP-1 is itself an incretin hormone — it directly amplifies glucose-dependent insulin secretion from beta cells after meals, lowering postprandial glucose spikes.
• Beta cell protection. GLP-1 receptor activation may reduce beta cell apoptosis (cell death) that occurs during chronic glucotoxicity, preserving the functional beta cell mass that remains.
• Glucagon suppression. GLP-1 inhibits glucagon secretion from alpha cells, reducing hepatic glucose output — the primary driver of elevated fasting glucose in prediabetes.
• Weight loss impact on insulin sensitivity. Each kilogram of body weight lost is associated with a 13–16% reduction in diabetes risk, and the visceral fat reduction produced by GLP-1 therapy is particularly potent for insulin sensitivity.

Is the Reversal Durable After Stopping Treatment?

The STEP 1 extension phase, which followed participants for one year after stopping semaglutide, provided a sobering but important answer: the majority regained weight when treatment was stopped, and prediabetes returned. Blood glucose levels drifted back toward the prediabetic range within months of discontinuation in most patients.

This is the critical practical implication: for patients with underlying insulin resistance and genetic predisposition to type 2 diabetes, GLP-1 therapy functions as an ongoing suppressive treatment rather than a curative one. Stopping it in a high-risk patient allows the underlying metabolic dysfunction to reassert itself. For truly high-risk prediabetic patients, long-term or indefinite treatment is likely necessary to maintain glycemic normalization.

The prediabetes window is the most important intervention opportunity in the entire natural history of metabolic disease. Before permanent beta cell loss has occurred, reversal is achievable. Once type 2 diabetes is fully established, management shifts from reversal to control. The urgency of intervening in prediabetes cannot be overstated.

Who Currently Qualifies for GLP-1 Medications With Prediabetes

GLP-1 medications are not currently FDA-approved specifically for prediabetes. Approved indications are type 2 diabetes (Ozempic, Rybelsus, Mounjaro, Trulicity) and obesity (Wegovy, Zepbound). However, patients with prediabetes and obesity can access GLP-1 therapy through the obesity indication:

• BMI ≥30 (obesity): qualifies for Wegovy or Zepbound without requiring a specific comorbidity.
• BMI ≥27 (overweight) with a weight-related comorbidity: prediabetes is generally recognized as a qualifying comorbidity under current prescribing guidelines for the obesity indication.
• Patients with prediabetes and established cardiovascular disease, hypertension, or dyslipidemia have particularly strong grounds for GLP-1 therapy under cardiovascular risk reduction indications.
• GLP-1 therapy for pure prediabetes prevention in a patient who does not meet obesity or CV risk criteria does not have an established FDA-approved pathway — off-label use requires individual provider judgment.

Lifestyle Remains the Foundation

The Diabetes Prevention Program (DPP) established that intensive lifestyle modification — 7% body weight loss and 150 minutes per week of moderate physical activity — reduces progression from prediabetes to type 2 diabetes by 58%. This remains the first-line recommendation. GLP-1 medications are additive to lifestyle intervention, not a replacement for it. The combination of pharmacological support and sustained behavioral change produces both greater weight loss and more durable glycemic normalization.

Monitoring Plan for Prediabetes on GLP-1 Therapy

• HbA1c at baseline and every 3–6 months. Normoglycemia target is HbA1c below 5.7%.
• Fasting glucose: useful for interim monitoring between HbA1c checks.
• Annual fasting insulin and HOMA-IR calculation (fasting insulin × fasting glucose ÷ 405) to track insulin resistance improvement over time.
• If HbA1c reaches 6.5% or above despite GLP-1 therapy and lifestyle changes, this indicates progression to type 2 diabetes requiring revised treatment strategy.
• Hypoglycemia risk is very low with GLP-1 medications alone (they are glucose-dependent), but remains a monitoring consideration if other glucose-lowering agents are added.

Sources

• Drucker DJ (2018). Mechanisms of Action and Therapeutic Application of GLP-1. Cell Metabolism.
• Marso et al. (2016). Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes. NEJM.